Northern Trust
LBRX

Northern Trust’s LB Pharmaceuticals LBRX Stock Holding History

Northern Trust’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.04M Buy
186,037
+31,639
+20% +$929K ﹤0.01% 2516
2026
Q1 		$3.81M Buy
154,398
+10,432
+7% +$241K ﹤0.01% 2613
2025
Q4 		$3.2M Buy
+143,966
New +$2.51M ﹤0.01% 2732

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Northern Trust's LBRX Position: Q2 2026 in Review

Northern Trust increased its LB Pharmaceuticals (LBRX) stake by 20% in Q2 2026, buying an estimated $929K and bringing the position to 186,037 shares worth $6.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2516.

Northern Trust first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Northern Trust held 186,037 shares of LB Pharmaceuticals worth $6.04M as of Q2 2026.
  • Northern Trust bought 31,639 LB Pharmaceuticals shares in Q2 2026, an estimated $929K.
  • LB Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2516 holding.
  • Northern Trust first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.